Business Description

Boiron SA
ISIN : FR0000061129
Share Class Description:
XPAR:BOI: Ordinary SharesCompare
Compare
Traded in other countries / regions
BOI.FranceBON.Germany0DTF.UKBOIRF.USA IPO Date
1989-07-27Description
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.59 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | 0.27 | |||||
Interest Coverage | 28.98 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.74 | |||||
Beneish M-Score | -2.62 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.1 | |||||
3-Year EBITDA Growth Rate | -11.4 | |||||
3-Year EPS without NRI Growth Rate | -15 | |||||
3-Year FCF Growth Rate | -16.5 | |||||
3-Year Book Growth Rate | -7.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 11.12 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.08 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.12 | |||||
9-Day RSI | 40.69 | |||||
14-Day RSI | 41.59 | |||||
3-1 Month Momentum % | -3.02 | |||||
6-1 Month Momentum % | -20.43 | |||||
12-1 Month Momentum % | -28.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.25 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 0.47 | |||||
Days Inventory | 279.15 | |||||
Days Sales Outstanding | 61.28 | |||||
Days Payable | 112.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 5.4 | |||||
Dividend Payout Ratio | 0.98 | |||||
3-Year Dividend Growth Rate | 1.6 | |||||
Forward Dividend Yield % | 5.4 | |||||
5-Year Yield-on-Cost % | 3.39 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 6.17 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 72.84 | |||||
Operating Margin % | 6.7 | |||||
Net Margin % | 4.92 | |||||
FCF Margin % | 5.14 | |||||
ROE % | 5.39 | |||||
ROA % | 3.74 | |||||
ROIC % | 5.03 | |||||
3-Year ROIIC % | 55.08 | |||||
ROC (Joel Greenblatt) % | 13.39 | |||||
ROCE % | 6.24 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.13 | |||||
Forward PE Ratio | 11.36 | |||||
PE Ratio without NRI | 17.85 | |||||
Shiller PE Ratio | 7.11 | |||||
Price-to-Owner-Earnings | 7.66 | |||||
PS Ratio | 0.89 | |||||
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 1.69 | |||||
Price-to-Free-Cash-Flow | 17.3 | |||||
Price-to-Operating-Cash-Flow | 10.04 | |||||
EV-to-EBIT | 12.45 | |||||
EV-to-Forward-EBIT | 5.75 | |||||
EV-to-EBITDA | 7.07 | |||||
EV-to-Forward-EBITDA | 3.78 | |||||
EV-to-Revenue | 0.82 | |||||
EV-to-Forward-Revenue | 0.69 | |||||
EV-to-FCF | 15.99 | |||||
Price-to-GF-Value | 0.61 | |||||
Price-to-Projected-FCF | 0.68 | |||||
Price-to-Median-PS-Value | 0.5 | |||||
Price-to-Graham-Number | 1.16 | |||||
Price-to-Net-Current-Asset-Value | 6.03 | |||||
Earnings Yield (Greenblatt) % | 8.03 | |||||
FCF Yield % | 5.7 | |||||
Forward Rate of Return (Yacktman) % | -4.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Boiron SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 481.711 | ||
EPS (TTM) (€) | 1.36 | ||
Beta | 0.04 | ||
3-Year Sharpe Ratio | -0.35 | ||
3-Year Sortino Ratio | -0.46 | ||
Volatility % | 21.17 | ||
14-Day RSI | 41.59 | ||
14-Day ATR (€) | 0.734176 | ||
20-Day SMA (€) | 25.255 | ||
12-1 Month Momentum % | -28.81 | ||
52-Week Range (€) | 24.3 - 36.35 | ||
Shares Outstanding (Mil) | 17.36 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Boiron SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Boiron SA Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Boiron SA Frequently Asked Questions
What is Boiron SA(XPAR:BOI)'s stock price today?
The current price of XPAR:BOI is €24.65. The 52 week high of XPAR:BOI is €36.35 and 52 week low is €24.30.
When is next earnings date of Boiron SA(XPAR:BOI)?
The next earnings date of Boiron SA(XPAR:BOI) is .
Does Boiron SA(XPAR:BOI) pay dividends? If so, how much?
The Dividend Yield %  of Boiron SA(XPAR:BOI) is 5.4% (As of Today), Highest Dividend Payout Ratio of Boiron SA(XPAR:BOI) was 0.98. The lowest was 0.27. And the median was 0.41. The  Forward Dividend Yield % of Boiron SA(XPAR:BOI) is 5.4%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |